IBRD only vs Latvia: Prevalence of current tobacco use
Prevalence of current tobacco use over time
- IBRD only
- Latvia
How they compare
Latvia currently reports 34.6% against 22.1% in IBRD only, a difference of 12.5%.
That makes Latvia's figure about 1.6 times IBRD only's.
Across all 9 years both countries report, Latvia has been ahead every year.
IBRD only ranks 16th and Latvia ranks 15th of 46 groups.
Latvia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | IBRD only | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 32.6% | 42.5% | 9.9% | Latvia |
| 2010s | 27.4% | 38.9% | 11.5% | Latvia |
| 2020s | 22.8% | 35.2% | 12.4% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of current tobacco use, IBRD only or Latvia?
- Latvia, at 34.6% against 22.1% in IBRD only as of 2024.
- What is the difference in prevalence of current tobacco use between IBRD only and Latvia?
- 12.5%, with Latvia ahead.
- How many years of comparable data are there for IBRD only and Latvia?
- 9 years are reported by both, from 2000 to 2024.
- How do IBRD only and Latvia rank globally for prevalence of current tobacco use?
- IBRD only ranks 16th and Latvia ranks 15th of 46 groups.
- Where does this data come from?
- Global Health Observatory Data Repository, World Health Organization (WHO), published as Prevalence of current tobacco use (% of adults). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of the population ages 15 years and over who currently use any tobacco product (smoked and/or smokeless tobacco) on a daily or non-daily basis. Tobacco products include cigarettes, pipes, cigars, cigarillos, waterpipes (hookah, shisha), bidis, kretek, heated tobacco products, and all forms of smokeless (oral and nasal) tobacco. Tobacco products exclude e-cigarettes (which do not contain tobacco), “e-cigars”, “e-hookahs”, JUUL and “e-pipes”. The rates are age-standardized to the WHO Standard Population.